synthesize

{
  "ranked_hypotheses": [
    {
      "title": "BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability requires proximal validation",
      "description": "The debate supports carrying forward BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability only if a proximal endpoint changes before the late outcome. The decisive validation path is: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration.",
      "target_gene": "BDNF",
      "dimension_scores": {
        "evidence_strength": 0.57,
        "novelty": 0.64,
        "feasibility": 0.69,
        "therapeutic_potential": 0.58,
        "mechanistic_plausibility": 0.67,
        "druggability": 0.5,
        "safety_profile": 0.55,
        "competitive_landscape": 0.55,
        "data_availability": 0.63,
        "reproducibility": 0.66
      },
      "composite_score": 0.604,
      "evidence_for": [
        {
          "claim": "Preregistered claim: BDNF-mediated hippocampal synaptic rescue restores CA3-CA1 connectivity and prevents downstream tau-mediated neurodegeneration in AD",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ],
      "evidence_against": [
        {
          "claim": "neurotrophic rescue may improve plasticity markers without interrupting amyloid or tau-driven degeneration",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ]
    },
    {
      "title": "Stratified falsifiers should govern AD Master Plan preregistration: BDNF",
      "description": "Claims from this analysis should be evaluated across BDNF, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.",
      "target_gene": "AD",
      "dimension_scores": {
        "evidence_strength": 0.54,
        "novelty": 0.59,
        "feasibility": 0.74,
        "therapeutic_potential": 0.5,
        "mechanistic_plausibility": 0.61,
        "druggability": 0.43,
        "safety_profile": 0.59,
        "competitive_landscape": 0.53,
        "data_availability": 0.68,
        "reproducibility": 0.7
      },
      "composite_score": 0.591,
      "evidence_for": [
        {
          "claim": "The analysis question names specific entities or evaluation structure.",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ],
      "evidence_against": [
        {
          "claim": "The current record can still be confounded by stage, leakage, or artifact effects.",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ]
    },
    {
      "title": "BDNF should remain under review until replicated",
      "description": "The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.",
      "target_gene": "tau",
      "dimension_scores": {
        "evidence_strength": 0.52,
        "novelty": 0.55,
        "feasibility": 0.71,
        "therapeutic_potential": 0.52,
        "mechanistic_plausibility": 0.58,
        "druggability": 0.45,
        "safety_profile": 0.58,
        "competitive_landscape": 0.52,
        "data_availability": 0.65,
        "reproducibility": 0.69
      },
      "composite_score": 0.577,
      "evidence_for": [
        {
          "claim": "Concrete next test: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ],
      "evidence_against": [
        {
          "claim": "Promotion before replication would weaken quality control.",
          "source": "AD-MASTER-PLAN-BDNF-20260428030755"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "AD-MASTER-PLAN-BDNF-20260428030755",
      "source_type": "analysis",
      "target_id": "BDNF",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-BDNF-20260428030755",
      "source_type": "analysis",
      "target_id": "AD",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-BDNF-20260428030755",
      "source_type": "analysis",
      "target_id": "tau",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-BDNF-20260428030755",
      "source_type": "analysis",
      "target_id": "amyloid",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    }
  ],
  "synthesis_summary": "Consensus: AD Master Plan preregistration: BDNF is substantive enough for debate because it names BDNF-mediated hippocampal synaptic rescue as a modifier of CA3-CA1 vulnerability and can be tied to a concrete validation path: deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration. Dissent: neurotrophic rescue may improve plasticity markers without interrupting amyloid or tau-driven degeneration. The claim should remain under review until the falsifier or replication path is executed."
}